Preferred Label : atezolizumab;
Obsolete resource : false;
CISMeF synonym : MPDL3280A;
MeSH synonym : anti-PDL1; immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MDPL3280a heavy
chain), disulfide with human monoclonal MDPL3280a kappa-chain, dimer;
MeSH hyponym : RG-7446; MPDL-3280A;
UNII : 52CMI0WC3Y;
Origin ID : C000594389;
UMLS CUI : C4055433;
ATC code(s)
- CISMeF manual mappings
- Manual BTNT mappings - CISMeF
- MeSH indexing information
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- See also (suggested by CISMeF)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3406124/fr/tecentriq-atezolizumab-cancer-bronchique-non-a-petites-cellules-cbnpc
2023
false
false
false
France
evaluation of the transparency committee
Tecentriq
neoplasm, malignant
"u" lymphocyte
cancer
atezolizumab
due to
Cancer
atezolizumab
bronchus, nos
Cell
carcinoma, non-small-cell lung
cells
---
Summary Safety Review - Keytruda (pembrolizumab) and Tecentriq (atezolizumab) - Assessing
the Potential Risk of Aplastic Anemia
https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1691503886633
2023
false
false
false
Canada
French
drug evaluation
Drug-Related side effects and adverse reactions
pembrolizumab
antibodies, monoclonal, humanized
atezolizumab
Antineoplastic Agents, Immunological
risk assessment
anemia, aplastic
Immune Checkpoint Inhibitors
canada
pharmacovigilance note
---
https://www.has-sante.fr/jcms/p_3390617/fr/tecentriq-atezolizumab-cancer-du-poumon
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
recurrence
carcinoma, non-small-cell lung
antineoplastic agents
infusions, intravenous
atezolizumab
Adjuvant Therapy
evaluation of the transparency committee
atezolizumab
---
https://ansm.sante.fr/tableau-atu-rtu/atezolizumab-840-mg-solution-a-diluer-pour-perfusion
2021
false
false
false
France
French
guidelines for drug use
antineoplastic combined chemotherapy protocols
atezolizumab
Albumin-Bound Paclitaxel
paclitaxel
Atezolizumab/Nab-paclitaxel Regimen
adult
triple negative breast neoplasms
summary of product characteristics
package leaflet
infusions, intravenous
atezolizumab
antineoplastic agents
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://ansm.sante.fr/informations-de-securite/tecentriq-atezolizumab-risque-de-reactions-cutanees-severes
2021
false
false
false
France
French
pharmacovigilance note
atezolizumab
risk
stevens-johnson syndrome
epidermal necrolysis, toxic
drug hypersensitivity syndrome
atezolizumab
antineoplastic agents
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3302587/fr/tecentriq-840-mg-atezolizumab
2021
false
false
false
France
French
insurance, health, reimbursement
atezolizumab
evaluation of the transparency committee
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
antineoplastic combined chemotherapy protocols
adult
neoplasm metastasis
carcinoma, non-small-cell lung
antineoplastic agents
atezolizumab
Advanced Adult Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma
carcinoma, hepatocellular
bronchial neoplasms
small cell lung carcinoma
Extensive Stage Lung Small Cell Carcinoma
treatment outcome
---
https://www.has-sante.fr/jcms/p_3240699/fr/tecentriq-carcinome-hepatocellulaire-chc
2021
false
false
false
France
atezolizumab
insurance, health, reimbursement
treatment outcome
atezolizumab
carcinoma, hepatocellular
atezolizumab
antineoplastic combined chemotherapy protocols
Bevacizumab
adult
Atezolizumab/Bevacizumab Regimen
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
Advanced Adult Hepatocellular Carcinoma
continuity of patient care
infusions, intravenous
guidelines for drug use
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3298586/fr/tecentriq-840-1200-mg-atezolizumab-monotherapie-cbnpc
2021
false
false
false
France
treatment outcome
carcinoma, non-small-cell lung
insurance, health, reimbursement
atezolizumab
antineoplastic agents
atezolizumab
infusions, intravenous
adult
neoplasm metastasis
PD-L1 Positive
PD-L1 Overexpression
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3214273/fr/tecentriq
2020
false
false
false
France
atezolizumab
treatment outcome
insurance, health, reimbursement
adult
antineoplastic combined chemotherapy protocols
Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel Regimen
bronchial neoplasms
carcinoma, non-small-cell lung
antineoplastic agents
neoplasm metastasis
evaluation of the transparency committee
atezolizumab
antibodies, monoclonal
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3184911/fr/tecentriq-cbpc
2020
false
false
false
France
antineoplastic agents
atezolizumab
adult
antineoplastic combined chemotherapy protocols
etoposide
carboplatin
bronchial neoplasms
small cell lung carcinoma
infusions, intravenous
insurance, health, reimbursement
evaluation of the transparency committee
atezolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3167438/fr/tecentriq-cancer-du-sein-triple-negatif-carcinome-urothelial-et-cbnpc
2020
false
false
false
France
atezolizumab
guidelines for drug use
triple negative breast neoplasms
infusions, intravenous
antineoplastic agents
treatment outcome
insurance, health, reimbursement
carcinoma, non-small-cell lung
urologic neoplasms
Urothelial Carcinoma
adult
neoplasm metastasis
antineoplastic combined chemotherapy protocols
evaluation of the transparency committee
atezolizumab
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3119783/fr/tecentriq
2019
false
false
false
France
atezolizumab
atezolizumab
infusions, intravenous
adult
antineoplastic combined chemotherapy protocols
Albumin-Bound Paclitaxel
carboplatin
carcinoma, non-small-cell lung
bronchial neoplasms
neoplasm metastasis
evaluation of the transparency committee
Tecentriq
antibodies, monoclonal
---
https://www.ansm.sante.fr/actualites/cancer-du-sein-lansm-met-a-disposition-deux-nouveaux-traitements-innovants
2019
false
false
false
France
French
drug information
innovative therapies
atezolizumab
antineoplastic agents
Ado-Trastuzumab Emtansine
breast neoplasms
therapies, investigational
---
https://www.has-sante.fr/portail/jcms/c_2965862/fr/tecentriq
2019
false
true
false
false
France
Urothelial Carcinoma
urologic neoplasms
antineoplastic agents
atezolizumab
adult
carcinoma, transitional cell
carcinoma, non-small-cell lung
evaluation of the transparency committee
atezolizumab
antibodies, monoclonal
---
https://www.ansm.sante.fr/actualites/lansm-octroie-une-atu-de-cohorte-dextension-dindication-pour-lutilisation-de-tecentriq-atezolizumab-dans-le-cancer-bronchique-a-petites-cellules
2019
false
false
false
France
French
bronchial neoplasms
small cell lung carcinoma
atezolizumab
antineoplastic agents
atezolizumab
drug information
adult
antineoplastic combined chemotherapy protocols
guidelines for drug use
continuity of patient care
antibodies, monoclonal
---
TECENTRIQ (atezolizumab) - Risk of Immune-Related Myositis
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69274a-fra.php
2019
false
false
false
Canada
French
English
pharmacovigilance note
atezolizumab
Metastatic Urothelial Carcinoma
carcinoma, non-small-cell lung
urinary bladder neoplasms
myositis
antineoplastic agents
infusions, intravenous
atezolizumab
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3113584/fr/tecentriq
2019
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
atezolizumab
antineoplastic agents
infusions, intravenous
atezolizumab
antineoplastic combined chemotherapy protocols
Bevacizumab
paclitaxel
carboplatin
adult
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
neoplasm metastasis
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
antibodies, monoclonal
---
TECENTRIQ (atezolizumab) - Risk of Immune-Related Nephritis
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/67782a-fra.php
2018
false
false
false
Canada
French
English
pharmacovigilance note
infusions, intravenous
atezolizumab
continuity of patient care
nephritis
nephritis
antineoplastic agents
urologic neoplasms
carcinoma, non-small-cell lung
nephritis
atezolizumab
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2856045/fr/tecentriq-poumon
2018
false
false
false
France
French
atezolizumab
treatment outcome
antineoplastic agents
adult
aged
infusions, intravenous
B7-H1 Antigen
CD274 protein, human
carcinoma, non-small-cell lung
evaluation of the transparency committee
neoplasm metastasis
Locally Advanced Malignant Neoplasm
atezolizumab
antibodies, monoclonal
---
https://ansm.sante.fr/informations-de-securite/tecentriq-r-atezolizumab-v-restriction-dindication-dans-le-traitement-des-patients-adultes-atteints-dun-carcinome-urothelial-localement-avance-ou-metastatique-ineligibles-a-une-chimiotherapie-a-base-de-cisplatine
2018
false
false
false
France
French
guidelines for drug use
atezolizumab
atezolizumab
infusions, intravenous
antineoplastic agents
adult
neoplasm metastasis
Locally Advanced Malignant Neoplasm
Urothelial Carcinoma
urologic neoplasms
survival analysis
antibodies, monoclonal
---
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/65990a-fra.php
2018
false
false
false
Canada
French
pharmacovigilance note
infusions, intravenous
atezolizumab
risk
myocarditis
antineoplastic agents
atezolizumab
guidelines for drug use
continuity of patient care
drug monitoring
myocarditis
Drug-Related side effects and adverse reactions
Invasive Bladder Urothelial Carcinoma
urinary bladder neoplasms
myocarditis
signs and symptoms
patients guideline
antibodies, monoclonal
---
https://ansm.sante.fr/tableau-marr/atezolizumab
2018
false
false
false
France
French
atezolizumab
atezolizumab
atezolizumab
Drug-Related side effects and adverse reactions
risk management
scientific and technical information
patient education handout
Drug-Related side effects and adverse reactions
signs and symptoms
antineoplastic agents
antineoplastic agents
immune system diseases
immune system diseases
antibodies, monoclonal
antibodies, monoclonal
---
https://www.ema.europa.eu/medicines/human/EPAR/Tecentriq
2017
false
false
false
United Kingdom
French
English
atezolizumab
atezolizumab
drug approval
treatment outcome
antineoplastic agents
antineoplastic agents
neoplasm metastasis
Locally Advanced Malignant Neoplasm
Bladder Urothelial Carcinoma
disease progression
adult
aged
infusions, intravenous
B7-H1 Antigen
antibodies, monoclonal, humanized
syndication feed
summary of product characteristics
package leaflet
drug evaluation
CD274 protein, human
europe
carcinoma, non-small-cell lung
product surveillance, postmarketing
pregnancy
breast feeding
survival analysis
drug evaluation, preclinical
urinary bladder neoplasms
atezolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
antibodies, monoclonal
---
Summary Basis of Decision (SBD) for Tecentriq
Atezolizumab 1200 mg/vial, solution, intravenous
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00356
2017
false
false
false
Canada
French
English
atezolizumab
drug information
atezolizumab
drug approval
canada
treatment outcome
antineoplastic agents
antineoplastic agents
neoplasm metastasis
Locally Advanced Malignant Neoplasm
Urothelial Carcinoma
disease progression
adult
aged
infusions, intravenous
B7-H1 Antigen
antibodies, monoclonal, humanized
urinary bladder neoplasms
CD274 protein, human
atezolizumab
antibodies, monoclonal, humanized
---
